🇺🇸 FDA

Drug profile · INN

lidocaine

LIGNOCAINE INJECTION (BRIDGEWEST)

approved N01BB20
US status
approved
Patents linked
2
News articles
0

Quick answer

lidocaine (LIGNOCAINE INJECTION (BRIDGEWEST)) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN lidocaine
Brand LIGNOCAINE INJECTION (BRIDGEWEST)
Route TOPICAL
Formulation SOLUTION
ATC code N01BB20
Originator Lacuna Pharma Pty Ltd

Related patents

Search patents →

  1. US 6528097

    Sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres

    Expires Mon Feb 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  2. US 6217911

    sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres

    Expires Mon Apr 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is lidocaine?

lidocaine (LIGNOCAINE INJECTION (BRIDGEWEST)) is an FDA-listed pharmaceutical active ingredient. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for lidocaine?

LIGNOCAINE INJECTION (BRIDGEWEST) is a marketed brand name for lidocaine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lidocaine?

lidocaine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.